Macrogenics (MGNX) Provides Update on Corporate Progress, TAMARACK Phase 2 Study Data, Q1 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. RNG
2. WDC
3. DECK
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. FIX

Go back to Macrogenics (MGNX) Provides Update on Corporate Progress, TAMARACK Phase 2 Study Data, Q1 Results

MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim TAMARACK Phase 2 Study Data

May 9, 2024 4:01 PM EDT

Presentation of interim TAMARACK Phase 2 study data: updated safety and preliminary efficacy of vobra duo in mCRPC patientsConference call scheduled for today at4:30 p.m. ET

ROCKVILLE, Md., May 09, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an update on its recent corporate progress and reported financial results for the quarter ended March 31, 2024.

We are very encouraged by the interim updated safety and... More